Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-04 am EDT			5-day change	1st Jan Change
326.30 ^DKK	+9.02%		+0.43%	-30.04%

Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI

Barclays cuts Zealand Pharma price target to DKK 425 (560), reiterates Overweight - BN

Published on 05/12/2026 at 03:11 am EDT

Finwire - Translated by Marketscreener - See original

ZEALAND PHARMA A/S

+9.02%

Barclays has lowered its price target for Zealand Pharma to DKK 425 from DKK 560, while maintaining its Overweight rating, according to Bloomberg News.

Latest news about Zealand Pharma A/S

Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI
Jun. 03	Deutsche Bank raises Zealand Pharma price target to DKK 300 (275), reiterates Hold	FW
Jun. 01	BNP Paribas raises Zealand Pharma price target to DKK 350 (275), reiterates Neutral - BN	FW
May. 26	Zealand Pharma A/S Elects Camilla Sylvest to the Board of Directors	CI
May. 15	U.S. Futures Down, European Stocks Fall	DJ
May. 14	Zealand Pharma A/S commences an Equity Buyback Plan, under the authorization approved on March 26, 2026.	CI
May. 12	Barclays cuts Zealand Pharma price target to DKK 425 (560), reiterates Overweight - BN	FW
May. 08	Goldman Sachs trims Zealand Pharma price target to DKK 471 (491), reiterates Buy - BN	FW
May. 07	Zealand Pharma A/S, Q1 2026 Earnings Call, May 07, 2026
May. 07	Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	DNB Carnegie raises Zealand Pharma price target to DKK 440 (425), reiterates Buy	FW
May. 07	U.S. Futures, European Stocks Mostly Up	DJ
May. 07	Zealand Pharma Kicks Off DKK1.3 Billion Share Buyback	MT
May. 07	Zealand Pharma Q1 EBIT loss DKK 539 mln	RE

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

544

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company